Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (865)	7/31/2008 2:43:35 AM
From: Doc Bones	Read Replies (1) of 897

From WSJ: Medivation said Dimebon seems to work by protecting the functioning of mitochondria, which generate energy for cells, during cellular stress. Dysfunction of mitochondria has been linked to both Alzheimer's and Huntington's diseases, according to the company. This mechanism is different from the approaches taken by other Alzheimer's drugs, said Medivation Chief Executive David Hung. Investors have learned to be skeptical of early data on new Alzheimer's treatments, as it can be hard to truly measure patient deterioration or improvement, especially concerning early or midstages of the disease. Medivation shares were down 48 cents to $19.29 in 4 p.m. Nasdaq Stock Market composite trading, and fell a further 19 cents in after-hours trading.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next